RxDoctor Payments Data

Mohamed Elamin, MD

Cardiovascular Disease · Cleveland, OHNPI 1912228503

Payments from drug & device makers

$1,011in general payments, 2019–2025

Across 37 payments — averaging $27.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$241
  • Pfizer$138
  • Astellas Pharma US Inc$121
  • Medtronic$102
  • Abbott$90
  • Johnson & Johnson$72
  • plus $246 from 9 others

What the payments were for

  • Food & beverage$91190%
  • Education$10010%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,011 in reported general payments places this provider in the 40th percentile of 827 cardiovascular disease providers in Ohio.

See all cardiovascular disease providers in Ohio

Medicare billing

Part B allowed, 2024
$79,664
Medicare patients
759
Services billed
1,205

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$64,053
EntrestoSacubitril/Valsartan32$42,182
FarxigaDapagliflozin Propanediol14$12,782
Metoprolol Succinate82$1,357
Ranolazine ErRanolazine13$1,061
Atorvastatin Calcium71$1,048
Bumetanide20$1,022
Warfarin Sodium68$737
Isosorbide Mononitrate ErIsosorbide Mononitrate38$469
Carvedilol37$378
Rosuvastatin Calcium17$340
ClopidogrelClopidogrel Bisulfate20$235
Ezetimibe13$232
Amiodarone Hcl13$228
Metoprolol Tartrate38$186

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$138$64,05350 claims
NovartisEntresto$30$42,18232 claims
AstraZenecaFarxiga$38$12,78214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 827 cardiovascular disease providers in Ohio.

Other cardiovascular disease in Cleveland

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →